Published online Mar 28, 2015. doi: 10.3748/wjg.v21.i12.3706
Peer-review started: September 4, 2014
First decision: October 14, 2014
Revised: October 31, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: March 28, 2015
AIM: To assess the prognostic value of c-Met status in colorectal cancer.
METHODS: We conducted a search in PubMed, Web of Science, and the Cochrane Library covering all published papers up to July 2014. Only studies assessing survival in colorectal cancer by c-Met status were included. This meta-analysis was performed by using STATA11.0.
RESULTS: Ultimately, 11 studies were included in this analysis. Meta-analysis of the hazard ratios (HR) indicated that patients with high c-Met expression have a significantly poorer overall survival (OR) (HR = 1.33, 95%CI: 1.06-1.59) and progression-free survival (PFS) (HR = 1.47, 95%CI: 1.03-1.91). Subgroup analysis showed a significant association between high c-Met expression and poorer overall survival in the hazard ratio reported (HR = 1.41, 95%CI: 1.08-1.74).
CONCLUSION: The present meta-analysis indicated that high c-Met expression was associated with poor prognosis in patients with colorectal cancer.
Core tip: High c-Met expression was found in colorectal cancer and showed a positive relationship with early tumor invasion and metastasis. However, there still seems to be no consensus about the prognostic properties of c-Met status. In this paper, after combing the data from 11 retrospective studies with 1,895 patients, the authors found that high c-Met expression was associated with poor prognosis in patients with colorectal cancer.